News
Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
3d
GlobalData on MSNModerna’s mRNA flu shot outperforms current standard at Phase IIIThe trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results